Динамика двигательных и когнитивных расстройств при болезни Паркинсона
Диссертация
Таким образом, проведенное исследование показало, что на фоне оптимальной противопаркинсонической терапии у больных БП продолжается нарастание двигательных, когнитивных и вегетативных нарушений. При этом прогрессирование двигательных и когнитивных нарушений происходит относительно независимо друг от друга, поскольку наибольший темп прогрессирования когнитивных и двигательных нарушений выявлялся… Читать ещё >
Содержание
- ГЛАВА 1. ОБЗОР ЛИТЕРАТУРЫ
- 1. 1. Двигательные нарушения при болезни Паркинсона
- 1. 2. Психические нарушения при болезни Паркинсона
- 1. 2. 1. Когнитивные нарушения
- 1. 2. 1. 1. Лечение когнитивных нарушений
- 1. 2. 2. Аффективные нарушения
- 1. 2. 3. Психотические нарушения
- 1. 2. 1. Когнитивные нарушения
- 1. 3. Вегетативные нарушения при болезни Паркинсона
- 1. 4. Лечение болезни Паркинсона
- ГЛАВА 2. МАТЕРИАЛЫ И МЕТОДЫ ИССЛЕДОВАНИЯ
- 2. 1. Общая характеристика обследованных больных
- 2. 2. Методы исследования
- ГЛАВА 3. РЕЗУЛЬТАТЫ ИССЛЕДОВАНИЯ
- 3. 1. Двигательные нарушения
- 3. 1. 1. Исходный уровень
- 3. 1. 2. Динамика двигательных нарушений
- 3. 2. Когнитивные нарушения
- 3. 2. 1. Исходный уровень
- 3. 2. 2. Динамика когнитивных функций
- 3. 2. 3. Динамика когнитивных нарушений в зависимости от их исходного состояния
- 3. 3. Соотношение двигательных и когнитивных нарушений
- 3. 4. Динамика аффективных нарушений и ее соотношение с динамикой когнитивных расстройств
- 3. 5. Динамика психотических нарушений и ее соотношение с динамикой когнитивных расстройств
- 3. 6. Динамика вегетативных нарушений и ее соотношение с динамикой других симптомов БП
- 3. 1. Двигательные нарушения
- ГЛАВА 4. ОБСУЖДЕНИЕ РЕЗУЛЬТАТОВ ИССЛЕДОВАНИЯ
Список литературы
- Лурия А.Р. Высшие корковые функции человека. М., МГУ, 2000 — С.512
- Лурия А.Р. Основы нейропсихологии. М., Изд-во МГУ, 1973 С.378
- Практикум по общей экспериментальной и прикладной психологии. Под ред. Крылова A.A., Маничева С. А. СПб.: Питер, 2000 — С.560
- Протокол ведения больных. Болезнь Паркинсона.//Проблемы стандартизации в здравоохранении, 2005. —N3. С.74−166.
- Рубинштейн С. Я. Экспериментальные методы патопсихологии и опыт применения их в клинике. М., Медицина, 1970 С.215
- Смоленцева И.Г. Влияние агонистов дофаминовых рецепторов на двигательные и нейропсихологические расстройства у больных с болезнью Паркинсона. Автореф. дисс. канд мед. наук., М., 2000 24 с.
- Федорова Н.В. Лечение и реабилитация больных паркинсонизмом.//Автореф. дис. докт. мед. наук.-М., 1996.
- Хомская Е.Д. Нейропсихология//- СПб.: Питер, 2005 С.496
- Шток В.Н. Лечение паркинсонизма/ В. Н. Шток, Н. В. Федорова. М., 1997.- С. 196. Экстрапирамидные расстройства. Под ред. В. Н. Штока, И.А. Ивановой-Смоленской, О. С. Левина — М.: «МЕДпресс-информ», 2002 -С.608.
- Шток В.Н., Левин О. С., Федорова Н. В. Экстрапирамидные расстройства. -М., 1998.-128 с.
- Штульман Д.Р., Левин О. С. Умеренные когнитивные нарушения // Неврология. Справочник практического врача. М., Мед. пресс-информ, 2005.- 4-е изд. С. 226−229.
- Яхно H.H. Актуальные вопросы нейрогериатрии//В кн.: Достижения в нейрогериатрии. М., 1995.-С.9−27.
- Яхно Н. Н. Дамулин И. В., Гончаров О. А. Сравнительная оценка различных форм паркинсонизма у больных пожилого и старческого возраста.// Журнал невролог, и психиатр. Им. С. С. Корсакова, 1992. T.92.-N-1.-С. 67−72.
- Яхно Н.Н., Штульман Д. Р., Мельничук П. В. Паркинсонизм//Болезни нервной системы.-М., 1995.-Т.2.-С.144−159.
- Aarsland D, Cummings JL, Larsen JP. Neuropsychiatrie differences between Parkinson’s disease with dementia and Alzheimer’s disease. Int J Geriatr Psychiatry 2001- 16:184−191.
- AarsIand D, Tandberg E, Larsen JP, Cummings JL. Frequency of dementia in Parkinson disease. Arch Neurol 1996- 53:538−542.
- Aarsland D, Zaccai J, Brayne С (1993) A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 20:1255−1263
- Aarsland D., Andersen K., Larsen J.P., et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study//Arch Neurol., 2003. -V60.-P. 387−392.
- Aarsland D., Bronnick. K, Ehrt U. Neuropsychiatrie symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress. //J. Neurol. Neurosurg. Psychiatry, 2007. -V.78. -P.36−42.
- Aarsland O, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study, J Neurol Neurosurg Psychiatry 2002- 72:708−712.
- Aarsland O, Larsen Jp, Cummings JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999a- 56:595−601.
- Aarsland O, Larsen Jp, Lim NG, Tandberg E. Olanzapine for psychosis in patients with Parkinson’s disease with and without dementia. J Neuropsychiatry ClinNeurosci 1999b- 11:3924.
- Aarsland O, Tandberg E, Larsen Jp, Cummings JL. Frequency of dementia in Parkinson’s disease. Areh Neurol 1996- 53:538−42.
- Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, Grandinetti A, Blanchette PL, Popper JS, Ross GW (2001) Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 57:456−462
- American Psychiatric Association. Oiagnostic and statistical manual of mental disorders, 4th edition, (OSM IV). Washington, OC: American Psychiatric Association, 1994.
- Apaydin H, Ahlskog JE, Parisi JE, Boeye BF, Dickson DW. Parkinson disease neuropathology: later-develOping dementia and loss of the levodopa response. Arch Neurol 2002- 59: 102−112.
- Arai H, Muramatsu T, Higuchi S, Sasaki H, Trojanowski JQ. Apolipoprotein E gene in Parkinson’s disease with and without dementia. Lancet 1994- 344:889.
- Ballard C, Holmes C, McKeith I, Neill D, O’Brien J, Cairns N, et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer’s disease. Am J Psychiatry 1999- 156:1039−1045.
- Ballard C. G., Chalmers K. A., Todd C., et al. Cholinesterase inhibitors reduces cortical amyloid-beta in dementia with Lewy bodies.//Neurology, 2007. -V.68. -P. 1726−1729.
- Ballard C., Lane R., Barone P. et al. Cardiac safety of rivastigmine in Lewy body and Parkinson’s disease dementia. // Int.J.Clin.Pract., 2006. V.60.-P.639−645.
- BalIard CG, Aarsland D, McKeith 1, Gray A, Cormack F, Burn D, et al. Attention and fluctuating attention in Parkinson’s disease with and without dementia and dementia with Lewy bodies. Neurology 2002- 58(Suppl. 3):A379.
- Beck A.T., Ward C.H., Mendelson M. et al. An inventory for measuring depression. Arch GenPsychiat 1961- 4: 561—571.
- Bey er MK, Herlofson K, Arsland D, Larsen JP (2001) Causes of death in a community-based study of Parkinson’s disease. Acta Neurol Scand 103:7−11
- Boeve BF, Silber MH, Ferman tk, et al. REM sleep disorder and degenerative dementia: an association likely reflecting Lewy body disease. Neurology 1998- 52:363−70.
- Boiler F, Passafiume D, Keefe NC. Rogers K, Morrow L, Kim Y. Visuospaiial impairment in Parkinson’s disease. Role of perceptual and motor factors. Arch Neurol 1984- 41:485−490.
- Boiler F, Mizutani T, Roessmann U, Gambetti P. Parkinson disease, dementia, and Alzheimer disease: clinicopatho lOgical correlations. Ann Neurol 1980−7:329−335.
- Bonnet AM, Loria Y, Saint Hilaire MH, Lhermitte F, Agid Y (1987) Does longterm aggravation of Parkinson’s disease result from nondopaminergic lesions? Neurology 37:1539−1542
- Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197−211
- Braak H., Del Tredici K., Bratzke H. et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages).//J.Neurology, 2002-V.249 (S.3)-P.l-5.
- Bronnick K., Emre M., Lane R., et al. Profile of cognitive impairment in dementia associated with Parkinson’s disease compared with Alzheimer’s disease.//J. Neurol. Neurosurg. Psychiatry, 2007. V.78. -P.1064−1068.
- Burn D.I., Emre M., McKeith I.G., et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease.//Mov.disord., 2006. V.21. -P.1899−1907.
- Burn D.J., Rowan E.N., Allan L.M., et al. Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies.//Neurol Neurosurg Psychiatry, 2006. -V. 77. P. 585−589.
- Burn D.J., McKeith I.G. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson’s disease.//Mov Disord 20 (Suppl. 6) (2003), pp. 72−79.
- Candy JM, Репу RH, Репу EK, Irving O, Blessed G, Fairbaim AF, et al. Pathological changes in the nucleus of Meynert in Alzheimer’s and Parkinson’s diseases. J Neurol Sci 1983−59:277 289.
- Cash R, Dennis T, L’Heureux R, Raisman R, Javoy-Agid F, Scatton B. Parkinson’s disease and dementia: norepinephrine and dopamine in locus ceruleus. NeurolOgy 1987- 37:42−46.
- Caviness J.N., Driver-Dunckley E., Connor D.J. et al. Defining mild cognitive impairment in Parkinson disease. //Mov.disord., 2007. -V.22. -P.1272−1277.
- Chaudhuri R.L., Healy O.G., Shapira A.H. Nonmotor symptoms 01 Parkinson’s disease//Lancet Neurology 2006. — V.5. — P 235−245.
- Churchyard A, Lees AJ. The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson’s disease. Neurology 1997- 49:1570−6.
- Cooper J.A., Sagar H.J. Jordan N. et al. Cognitive impairment in early untreated Parkinson’s disease and its relationship to motor disability // Brain.-1991.-Vol. 114.-Р/2095−2122.
- Cummings J.L. Cholinesterase inhibitors for treatment of dementia associated with Parkinson’s disease. //J. Neurol. Neurosurg. Psychiatry, 2005. V.76. — P. 903−904.
- Cummings JL, Darkins A, Mendez M, Hill MA, Benson DF. Alzheimer’s disease and Parkinson’s disease: comparison of speech and language alterations. Neurology 1988- 38:680−684.
- Cummings JL, Huber SJ. Visuospatial abnormalities in Parkinson’s disease. In: Huber SJ, Cummings JL, editors. Parkinson’s disease: behavioral and neuropsychological aspects. New York: Oxford Press- 1992. P 59−73.
- Cummings JL. Depression and Parkinson’s disease: a review. At J Psychiatry 1992−149:44 354.
- Cummings JL. Intellectual impairment in Parkinson’s disease: clinical, pathologic, and biochemical correlates. J Geriatric Psychiatry Neurol 1988- 1:2436.
- Cummings JL. Subcortical dementia: neuropsychology, neuropsychiatry and pathophysiology. Br J Psychiatry 1986- 149:682−97. *
- Cummings JL. The dementias of Parkinson’s disease: prevalence, characteristics, neurobiology, and comparison with dementia of the Alzheimer type. Eur Neurol 1988- 28(Suppl. l):15−23.
- Daniel SE, Lees AJ. Neuropathological features of Alzheimer’s disease in non-demented parkinsonian patients. J Neurol Neuro-surg Psychiatry 1991,54:972 975.
- Deuschl G., Bain P., Brin M. and Ad Hoc Scientific Committee. Consensus statement of the movement disorder society on tremor//Mov. disord., 1998.-V.13.(Supl. 3).-PP. 2−23
- De Vos RA, Jansen EN, Stam FC, Ravid R, Swaab DF. 'Lewy body disease': clinico-pathological correlations in 18 consecutive cases of Parkinson’s disease with and without dementia. Clin Neurol Neurosurg 1995−97: 13−22.
- Dubois B, Malapani C, Verin M, Rogelet P. Deweer B, Pillon B. Cognitive functions and the basal ganglia: the model of Parkinson disease. Rev Neurol (Paris) 1994- 150:763−770.
- Dubois B., Burn D., Goetz C. et al. Diagnostic procedures for Parkinson’s disease dementia: Recommendations from the movement disorder society task force.//Movement Disorders, 2007. V.22. -P. 2314−2324.
- Dubois B, Ruberg M, Javoy-Agid F, Ploska A, Agid Y. A subcortico-cortical cholinergic system is affected in Parkinson’s disease. Brain Res 1983- 288:213−218.
- Dubois B. Resultats cognitife de l’eude Parkinson CONTROL./ZDrugs in Focus, 2004, February, P. 19−22.
- Duvoisin RC. Genetic and environmental factors in Parkinson’s disease. Adv Neurol 1999- 80:161−3.
- Ebmeier Kp, Calder SA, Crawford JR, Stewart L, Besson JA, Mutch WJ. Clinical features predicting dementia in idiopathic Parkinson’s disease: a follow-up study. Neurology 1990- 40: 1222−4.
- Ellis RJ, Caligiuri M, Galasko O, Thai LJ. Extrapyramidal motor signs in clinically diagnosed Alzheimer disease. Alzheimer Dis Assoc Disord 1996- 1 o: 1 03−14.
- Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson’s disease.//N. Engl. J. Med., 2004. -V. 351. -P.2509−2518.
- Emre M. Dementia associated with Parkinson’s disease. // Lancet Neurol., 2003. -V.2. -P. 229−237.
- Emre M., Aarsland D., Brown R. et al. Clinical diagnostic criteria for dementia associated with Parkinson disease. //Mov.disord., 2007. -V.22. -P.1689−1707.
- Faber R, Trimble MR. Electroconvulsive therapy in Parkinson’s disease and other movement disorders. Mov Disord 1991- 6:293−303.
- Factor SA, Brown O, Molho ES, Podskalny GD. Clozapine: a 2-year open trial in Parkinson’s disease patients with psychosis. Neurology 1994- 44:544−6.
- Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351:2498−2508.
- Fahn S., Elton R. Unified Parkinson’s disease rating scale. Recent developments in Parkinson’s disease.// Fahn S., Marsden C., Calne D. et al. (Eds). McMillan Healthcare information.-V.5.-1987~P. 153−163.
- Fearnley JM, Lees AJ (1994) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114 (Pt 5):2283−2301
- Fenelon G, Mahieux F, Huon R. Ziegler M. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 2000- 123(Pt 4):733−745.
- Ferreri F., Agbokou C., Gauthier S. Recognition and management of neuropsychiatric complications in Parkinson’s disease.//CMAJ, 2006. V.175. -P.1545−1552.
- Fernandez HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the treatment of druginduced psychosis in Parkinson’s disease. Mov Disord 1999- 14:484−7.
- Fomo LS. Neuropathology of Parkinson’s disease. J Neuropalhol Exp Neurol 1996- 55:259−272.
- Folstein MF, Folstein SE, McHugh PR (1975). «„Mini-mental state“. A practical method for grading the cognitive state of patients for the clinician». Journal of psychiatric research 12 (3): 189−98
- Gauthier S., Touchon J. Subclassification of mild cognitive impairment in research and in clinical practice//Alzheimer' Disease and Related Disorders Annual, 2004.-P. 61−70.
- Galasko O, Katzman R, Salmon OP. Clinical and neuropathological findings in Lewy body dementia. Brain Cogn 1996- 3 1: 176−85.
- Galvin J.E., Pollack J., Morris J.C. Clinical phenotype of Parkinson disease dementia.//Neurology, 2006. V.67. -P.1605−1611.
- Gaspar P, Gray F. Dementia in idiopathic Parkinson’s disease. A neuropathological study of 32 cases. Acta Neuropathol (Berl) 1984- 64:43−52.
- Giladi N, Shabtai H, Gurevich T, Anca M, Sidis S, et al. The effect of treatment with rivastigmin (Exelon) on cognitive functions of patients with dementia and Parkinson’s disease. Neurology 200 1 -56(Suppl. 3):A 128.
- Gibb WR.G., Lees A.J. UK PDS Brain Bank Criteria 1988.
- Gibb WR. Dementia and Parkinson’s disease. Br J Psychiatrv 1989- 154:596−614. Golbe LI. Alpha-synuclein and Parkinson’s disease. Mov Disord 1999- 14:6−9.
- Girotti F, Soliveri P, Carella F, Piccolo I, Caffarra P, Musicco M, et al. Dementia and cognitive impairment in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988- 51:1498−1502.
- Goetz CG, Stebbins GT (1993) Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology 43:2227−2229
- Goetz CG, Tanner CM, Shannon KM (1987) Progression of Parkinson’s disease without levodopa. Neurology 37:695−698
- Goetz CG, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 1998, 51:811−814.
- Goldenberg G, Wimrner A, Auff E, Schnaberth G. Impairment of motor planning in patients with Parkinson’s disease: evidence from ideomotor apraxia testing. J Neurol Neurosurg Psychiatry 1986- 49:1266−1272.
- Goldman WP, Baty JD, Buckles VD, Sahrmann S, Morris JC. Cognitive and motor functioning in Parkinson’s disease. Arch Neurol 1998- 55:674−80.
- Grandinetti A, Blanchette PL, Popper JS, Ross GW (2001) Frequency of Grossman M, Carvell S, Gollomp S, Stem MB, Vernon G, Hurtig HI. Sentence comprehension and praxis deficits in Parkinson’s disease. Neurology 1991- 41:1620−1626.
- Hansen L, Samuel W. Criteria for Alzheimer disease and the nosology of dementia with Lewy bodies. Neurology 1997−48: 126−32.
- Hartmann S., Mobius H.J. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy.//Int. Clin. Psychopharmacology, 2003. -V.18. -P.81−85.
- Helkala EL, Laulumaa V, Soininen H, Riekkinen PJ. Different error pattern of episodic and semantic memory in Alzheimer’s disease and Parkinson’s disease with dementia. Neuropsychologia 1989- 27:1241−1248.
- Helkala EL, Laulumaa V, Soininen H, Riekkinen PJ. Recall and recognition memory in patients with Alzheimer’s and Parkinson’s diseases. Ann Neurol 1988- 24:214−217.
- Hely M.A., Morris J.G., Reid W.G. et al. Sydney multicenter study of Parkinson’s disease.//Mov. Diosrd., 2005. -V.20. -P.190−199.
- Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney Multicenter Study of Parkinson’s disease: non-Ldopa-responsive problems dominate at 15 years. Mov Disord 20:190−199
- Hely MA, Morris JG, Traficante R, Reid WG, 0'Sullivan DJ, Williamson PM (1999) The sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 67:300−307
- Hietanen M, Teravainen H. Dementia and treatment with L-dopa in Parkinson’s disease. Mov Disord 1988- 3:263−270.
- Hietanen M, Teravainen H. The effect of age of disease onset on neuropsychological performance in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988- 51:244−249.
- Hilker R., Thomas A.V., Klein J.C., et al. Dementia in Parkinson disease: Functional imaging of cholinergic and dopaminergic pathways.//Neurology, 2005. V.65. -P.1716−1722.
- Hobson P, Meara J. The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson’s disease by use of the CAMCOG neuropsychological test. Age Ageing 1999- 28:39−43.
- Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427−442
- Huber SJ, Shulman HG, Paulson GW. Shuttleworth EC. Fluctuations in plasma dopamine level impair memory in Parkinson’s disease. Neurology 1987- 37:1371−1375.
- Huber SJ. Shuttleworth EC, Freidenberg DL. Neuropsychological differences between the dementias of Alzheimer’s and Parkinson’s diseases. Arch Neurol 1989- 46:1287−1291.
- Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson’s disease. Arch Neurol 1993−50: 140−148.
- Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RH, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology 2000- 54: 1596−1602.
- Hurtig Hl, Trojanowski JQ, Galvin J, Ewbank O, Schmidt ML, Lee YM, e! al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 2000−54:1916−1921.
- Inzelberg R, Chapman J, Treves TA, Asherov A, Kipervasser S, Hilkewicz O, et al. Apolipoprotein E4 in Parkinson disease and dementia: new data and meta-analysis of published studies. Alzheimer Dis Assoc Disord 1998- 12:45−8.
- Inzellberg R. Association between amantadine and the onset of dementia in Parkinson disease. //Mov.disord., 2006. -V.21. P. 1375−1379.
- Inzellberg R., Bonuccelli U., Schechtman E. Association between amantadine and onset of dementia in Parkinson disease. //Mov.disord., 2006. -V.21. -P.1375−1379.
- Ishii k, Yamaji S, Kitagaki H, Imamura T, Hirono N, Mori E. Regional cerebral blood flow difference between dementia with Lewy bodies and Alzheimer’s disease. Neurology 1999- 53:413−6.
- Lichter D.G., Wray L., Hershey L.A. Memantine may alleviate psychosis and cognitive dysfunction in dementia with Lewy bodies .//Mov.disord., 2006. -V.21.-S.13.- S.112.
- Jacobs DM, Marder K, Cote U, Sano M, Stern Y, Mayeux R. Neuropsychological characteristics of preclinical dementia in Parkinson’s disease. Neurology 1995−45:1691−1696.
- Jenkinson C., Fitzpatrick R., Peto V. The PDQ-8: Development and validation of a short-form Parkinson’s disease questionnaire.//Psychology & Health, 1997. V. 12. — P. 805 — 814.
- Jellinger KA, Seppi K, Wenning GK, Poewe W (2002) Impact of coexistent Alzheimer pathology on the natural history of Parkinson’s disease. J Neural Transm 109:329−339
- Jellinger KA, Paulus W. Clinico-pathological correlations in Parkinson’s disease. Clin Neurol Neurosurg 1992−94(Suppl.):S86S88.
- Jellinger KA, Seppi K, Wenning OK, Poewe W. Impact 01' coexistent Alzheimer pathology on the natural history of Parkinson’s disease. J Neural Transm 2002- 1 09:329−339.
- Jellinger KA. Morphological substrates of dementia in Parkinsonism. A critical update. J Neural Transm Suppl 1997−51 :57−82.
- Jellinger K. Structural basis of dementia in Transm SuppI1996- 47:1−29.*
- Johns M.W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale.//Sleep, 1991. V. 14. -P.540−545.
- Kalra S, Bergeron C, Lang AE. Lewy body disease and dementia: a review. Arch Intern Med 1996- 156:487−93. **
- Kosaka K, Tsuchiya K, Yoshimura M. Lewy body disease with and without dementia: a clinicopathological study 01' 35 cases. Clin Neuropathol 1988−7:299−305.
- Kurlan R., Cummings J., Raman R., et al. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism.//Neurology, 2007. V.68. -P.1356−1363.
- Krogh K, Ostergaard K, Sabroe S, et al. Clinical aspects of bowel symptoms in Parkinson’s disease. Acta Neurol Scand 2008- 117: 60−64.
- Lee CS, Schulzer M, Male EK, Snow BJ, Tsui JK, Calne S, Hammerstad J, Calne DB (1994) Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 117:501−507.
- Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson’s disease. Brain 1983−106:257−70.
- Levin BE, Llabre MM, Reisman S, Weiner WJ, Sanchez-Ramos J, Singer C, et al. Visuospatial impairment in Parkinson’s disease. Neurology 1991- 41:365 369.
- Levin BE. Spatial cognition in Parkinson disease. Alzheimer Dis Assoc Disord 19 904:161−70.
- Levy G, Schupf N, Tang MX, Cote U, Louis ED, Mejia H, et al. Combined effect of age and severity on the risk of dementia in Parkinson’s disease. Ann Neurol 2002−51:722−729.
- Levy G, Tang MX, Cote U, Louis ED, Alfaro B, Mejia H, et al. Do risk factors for Alzheimer’s disease predict dementia in Parkinson’s disease? An exploratory study. Mov Disord 2002, 17: 250−257.
- Levy G, Tang MX, Cote U, Louis ED, Alfaro B, Mejia H, et al. Motor impairment in PD: relationship to incident dementia and age. Neurology 2000- 55:539−544.
- Lippa C. F., Duda J. E., Grossman M., et al. DLB and PDD boundary issues: Diagnosis, treatment, molecular pathology, and biomarkers.//Neurology, 2007.-V.68.-P. 812−819.
- Litvan I, Mohr E, Williams J, Gomez C, Chase TN. Differential memory and executive functions in demented patients with Parkinson’s and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1991- 54: 25−29.
- Louis ED, Marder K, Cote L, Tang M, Mayeux R (1997) Mortality from Parkinson disease. Arch Neurol 54: 260−264
- Louis ED, Klatka LA, Liu Y, Fahri S. Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson’s disease. Neurology 1997- 48: 376−80.
- Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Denefle P, Wood NW, Agid Y, Brice A (2000) Association between early-onset Parkinson’s disease and mutations in the parkin gene. N Engl J Med 342:1560−1567
- Marder K, Tang MX, Cote L, Stern Y, Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson’s disease. Arch Neurol 1995- 52:695−701.
- Mancini F., Manfredi L., Pacchetti C. Memantine and Parkinson’s disease./ZMov.disord., 2006. V.21. (S15) — P.901.
- Manos P.J., Wu R. The ten point clock test.//Int.J.Psych. Med., 1994. -V.24. -P.229−244.
- Mattis S. Dementia Rating Scale: Professional manual .//Odessa, FL: Psychological assessment resources, 1988.
- Marsden C.D., Fahn S. Problems in Parkinson s disease and other akinetik-rigid syndromes. Cambrridge, Butterworth Heinemann, 1994.-P. 117−123
- Martin WE, Loewenson RB, Resch JA, Baker AB. Parkinson’s disease. Clinical analysis of 100 patients. Neurology 1973- 23:783−790.
- Marttila RJ, Rinne UK, Siirtola T, Sonninen V (1977) Mortality of Patients with Parkinson’s Disease Treated with Levodopa. J Neurol 216:147−153
- Marttila RJ, Rinne UK. Epidemiology of Parkinson’s disease in Finland. Acta Neurol Scand 1976- 53:81−102.
- Matilla PM, Roytta M, Torikka H, Dickson DW, Rinne JO. Cortical Lewy bodies and Alzheimertype changes in patients with Parkinson’s disease. Acta Neuropathol 1998−95:576−82.*
- Marttila PM, Rinne 10, Helenius H, Dickson DW, Roytta M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease. Acta Neuropathol (Berl) 2000- 100:285−290.
- Marttila PM, Roytta M, Torikka H, Dickson DW, Rinne JO. Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson' 5 disease. Acta Neuropathol (Berl) 1998- 95: 576−582. .
- Matison R, Mayeux R, Rosen J, Fahn S. «Tip-of-the-tongue» phenomenon in Parkinson disease. Neurology 1982- 32:567−570.
- Mayeux R, Chen J, Mirabello E, Marder K, Bell K, Dooneief G, et al. An estimate of the incidence of dementia in idiopathic Parkinson’s disease. Neurology 1990- 40:1513−1517.
- Mayeux R, Denaro J, Hemenegildo N. Marder K, Tang MX, Cote U, et al. A population-based investigation of Parkinson’s disease with and without dementia. Relationship to age and gender. Arch Neurol 1992- 49:492−497.
- Mayeux R, Denaro J, Hemenegildo N, et al. A population based investigation of Parkinson’s disease with and without dementia. Arch Neurol 1992−49:492−7.**
- Mayeux R, Stern Y. Rosenstein R, Marder K, Hauser A, Cote L, et al. An estimate of the prevalence of dementia in idiopathic Parkinson’s disease. Arch Neurol 1988- 45:260−262.
- Marder K, Tang MX, Cote L, Stern Y, Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson’s disease. Arch Neurol 1995−52(7):695−701.
- Mendez M.F., Cummings J. Dementia. Philadelphia, Butterworth Heinemann, 2003. 654 C.
- Merrello M., Nouzeilles M.I., Cammarota A. et al. Effect of memantine (NMDA antagonist) on Parkinson’s disease.//Clin. Neuropharmacol., 1999. V.5. —P.l 11−126.
- McKeith 1, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992−305:673−8.
- Mega MS, Masterman DL, Benson DF, et al. Dementia with Lewy bodies: reliability and validity of clinical and pathological criteria. Neurology 1996−47: 1403−9.
- Molloy S. A., Rowan E.N., O’Brien J.T., et al. Effect of levodopa on cognitive function in Parkinson’s disease with and without dementia and dementia with Lewy bodies.//J. Neurol. Neurosurg. Psychiatry, 2006. V.77. — P. 13 231 328.
- Mortimer JA, Pirozzolo FJ, Hansch EC, Webster DD. Relationship of motor symptoms to intellectual deficits in Parkinson disease. Neurology 1982- 32:133−137.
- Muller J, Wenning GK, Verny M, McKee A, Chaudhuri ICR, Jellinger K, Poewe W, Litvan I (2001) Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch Neurol 58:259−264
- Nakano 1, Hirano A. Parkinson’s disease: neuron loss in the nucleus basalis without concomitant Alzheimer’s disease. Ann Neurol 1984- 15:415−418.
- Narabayashi H. Evidence suggesting the role of norepinephrine deficiency in late stages of Parkinson’s disease. //Adv.Neurol., V.80. -P.501−504.
- Nutt J G, Marsden CD, Thompson PD. Human walking and higher-level gait disorders, particularly in the elderly.// Neurology, 1993.- V.43.-P.268−279.
- Orgogozo J.M., Rigaud A.S., Stoffler A, et al. Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300).//Stroke, 2002. -V.33. -P.1834−1839.
- Owen A M, Roberts AC, Hodges JR, Summers BA, Polkey CE, Robbins TW. Contrasting mechanisms of impaired attentional set-shifting in patients with frontal lobe damage or Parkinson’s disease. Brain 1993- 116 (Pt 5): 1159−1175.
- Parkinson J. An essay on the shaking palsy. // London, 1817.-66p.
- Parkinson Study Group (2004) a controlled, randomized, delayed-start studies of rasagiline in early Parkinson disease. Arch Neurol 61:561−566
- Parsons C.G., Danysz W., Quack G. Memantine is clinically well tolerated NMDA-receptor antagonist.//Neuropharmacology, 1999. -V.38. -P.735−767.
- Perl OP, Olanow CW, Calne O. Alzheimer’s disease and Parkinson’s disease: distinct entities or extremes 01' a spectrum of nenrodegeneration? Ann Neurol1998−44(Suppl. 1): SI9-S31.
- Peskind E.R., Potkin S.G., Pomara N. et al. Memantine treatment in mild to moderate.
- Petersen R.C., Thomas R.G., Grundman M. et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005- 352:2379—2388.
- Pillon B, Boiler F, Levy R, Dubois B. Cognitive deficits and dementia in Parkinson’s disease. In: Boiler F, Cappa S, editors. Handbook of neuropsychology. 2nd ed. Amsterdam: Elsevier- 2001. P 311−371.
- Pillon B, Dcweer B, Agid Y, Dubois B. Explicit memory in Alzheimer’s, Huntington’s, and Parkinson’s diseases. Arch Neurol 1993- 50: 374−379.
- Pillon B, Dubois B, Cusimano G, Bonnet AM, Lhermitte F, Agid Y. Does cognitive impairment in Parkinson’s disease result from non-dopaminergic lesions? J Neurol Neurosurg Psychiatry 1989- 52:201−206.
- Pillon B, Dubois B, Lhermitte F, Agid Y. Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson’s disease, and Alzheimer’s disease. Neurology 1986- 36: 1179−1185.
- Pillon B, Dubois B, Ploska A, Agid Y. Severity and specificity of cognitive impairment in Alzheimer’s, Huntington’s, and Parkinson’s diseases and progressive supranuclear palsy. Neurology 1991- 41: 634−643.
- Poewe WH, Lees AJ, Stern GM (1986) Low-dose L-dopa therapy in Parkinson’s disease: a 6-year follow-up study. Neurology 36:1528−1530
- Ponsen MM, Stoffers D, Booij J, Eck-Smit BL, Wolters EC, Berendse HW (2004) Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol 56:173−181
- Postuma R.B., Lang A.E., Massicotte-Marquez J., et al. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder.//Neurology, 2006. -V.66. -P.845−851.
- Press D, Mechanic D, Manoach D. Working memory deficits in Parkinson’s disease resolve after consolidation. Mov Disord 2001- 16(Suppl. 1):S25.
- Rabey J.M., Nissipeanu P., Korczyn A.D. Efficacy of memantine an NMDA receptor antagonist in the treatment of Parkinson’s disease.//J.NeurolPark Dis Dement Sect, 1992. -V.4. P.272−282.
- Rajput AH, Offord KP, Beard CM, Kurland LT. A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson’s disease. Neurology 1987- 37: 226−232.
- Read N, Hughes TA, Dunn EM, Nirodi P, Branton T, Mindham RHS, Spokes EGS. Dementia in Parkinson’s disease: incidence and associated factors at 14-years of follow up. Parkinsonism Relat Disord 2001- 7(Suppl.):S 109.
- Reid WG, Hely MA, Morris JG, Broe GA, Adena M, Sullivan DJ, et al. A longitudinal study of Parkinson’s disease: clinical and neuropsychological correlates of dementia. J Clin Neurosci 1996- 3:327−333.
- Reisberg B., Doody R., Stoffler A., Schmitt F., et. al. Memantine in moderate-to-severe Alzheimer’s disease.//N. Engl. J. Med., 2003. -V. 348. -P. 1333−1341.
- Ridha B.H., Josephs K.A., Rossor M.N. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine.//Neurology, 2005. -V.65. -P.481−482.
- Riederer P., Lange K.W., Kornhuber J. Pharmacotoxic psychosis after memantine in Parkinson’s disease./ZLancet 1991. -V.338. -P.1022−1023.
- Rinne JO, Rummukainen J, Paljarvi L, Rinne UK. Dementia in Parkinson’s disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 1989, 26:47−50.
- Roland J.R., Rigby J., Harper A.C. et al. Cardiovascular monitoring with acetylcholinesterase inhibitors. //Adv. Psych. Treat., 2007. -V.13. -P. 178−184.
- Rogawski M.A., Wenk G.L. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease.//CNS drug review., 2003. -V.9. -P.275−308.
- Ruberg M, Agid Y. Dementia in Parkinson’s disease. In: Iversen L, Iversen S, Snyder S, editors. Handbook of psychopharmacology. New York: Plenum Press- 1988. p 157−206.
- Saint-Cyr JA, Taylor AE, Lang AE. Procedural learning and neo-striatal dysfunction in man. Brain 1988:11 1 (Pt 4):941−959.
- Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson’s disease. Brain Res 1983- 275:321−328.
- Schenck CH, Bundlie SR, Mahowald MW (1996) Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46: 388−393
- Schrag A, Quinn N (200) Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain 123 (Pt 11):2297−2305
- Shimomura T, Mori E, Yamashita H, et al. Cognitive loss in dementia with Lewy bodies and Alzheimer disease. Arch Neuroll 998- 55:1547−52.
- Scharre D.W. Galantamine with adjunctive memantine: combined effects on brain nicotinic acetylcholine receptors and NMDA receptors may improve Alzheimer’s disease symptomatology.//J.Clin. Pharmacol., 2006. -V.46. -P.6.
- Schwab J.F., England A.C. Projection technique for evaluating surgery in Parkinson disease.//In: Billingham F.H., Donaldson M.C. Third symposium on Parkinson disease. Edinburgh: Livingstone, 1969.-P.152−157.
- Starkstein S.E., Merello M. Psychiatric and cognitive disorders in Parkinson’s disease. Cambridge Universitu Press, 2002. -229 P.
- Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson RG. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1992- 55:377−382.
- Stem Y, Langston JW. Intellectual changes in patients with MPTP-induced Parkinsonism. Neurology 1985- 35:1506−1509.
- Stem Y, Marder K, Tang MX, Mayeux R. Antecedent clinical features associated with dementia in Parkinson’s disease. Neurology 1993- 43:1690−1692.
- Stem Y, Mayeux R, Rosen J, llson J. Perceptual motor dysfunction in Parkinson’s disease: a deficit in sequential and predictive voluntary movement. J Neurol Neurosurg Psychiatry 1983- 46:145−151.
- Stem Y, Tetrud JW, Martin WR, Kutner SJ, Langston JW. Cognitive change following MPTP exposure. Neurology 1990- 40:261−264.
- Stem Y, Mayenx R, Cote L. Reaction time and vigilance in Parkinson’s disease. Possible role of altered norepinephrine Tetabolism. Arch Neurol 1984−41:1086−1089.
- Stern Y, Richards M, Sano M, Mayeux R. Comparison of cognitive changes in patients with Alzheimer’s and Parkinson’s disease. Arch Neurol 1993- 50:1040−1045.
- Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson’s disease. Arch Neuroll 996- 53:1265−8.
- Taylor AE, Saint-Cyr JA, Lang AE. Frontallobe dysfunction in Parkinson’s disease: the cortical focus of neostriatal outflow. Brain 1986- 1 09:279−92.
- The Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328:176 183.
- The Parkinson Study Group (1996) Effect of lazabemide on the progression of disability in early Parkinson’s disease. Ann Neurol 40:99−107.
- Tocco M., Resnick E.M., Graham S. et al. Cognitive effects of memantine in moderate to severe Alzheimer’s disease: a responder analysis.// Eur J. Neurology, 2007. -V.14 (S.l)-P.1098.
- Verghese J, Crystal HA, Dickson DW, Lipton RB. Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology 1999- 53:1974−82.
- Villardita C, Smirni P, le Pira F. Zappala G, Nicoletti F. Mental deterioration, visuoperceptive disabilities and constructional apraxia in Parkinson’s disease. Acta Neurol Scand 1982- 66:112−120.
- Walker Z, Grace J, Overshot R, et al. Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatry 1999- 14:459−66.
- Watts RL, Koller WC, editors. Movement disorders. New York: Wenning G.K., Colosimo C., Geser F. et al. The role 01 cardiac MIBG uptake in the differential diagnosis 01 parkinsonian syndromes//Lancet Neurology. 2004. -V.3.-P 93−103.
- Wesnes K.A., McKeith I., Edgar C., et al. Benefits of rivastigmine on attention in dementia associated with Parkinson disease .//Neurology, 2005. -V.65.-P.1654−1656.
- Whitehouse PJ, Hedreen JC, White CL 111, Price DL. Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 1983- 13:243−248.
- Williams-Gray C. H., Foltynie T., Brayne C. E. G., et al. Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort.// Brain, 2007. — V.130. -P.1787 1798.
- Wilcock G.K. Memantine for the treatment of dementia.//Lancet Neurology, 2003. -V.2. -P.503−505.
- Wilkinson D., Andersen H.F. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer’s disease.//Dement. Geriatr. Cogn. Disord., 2007. -V.24. -P.138−145.
- Zakzanis K, Freedman M. A neuropsychological comparison of demented and nondemented patients with Parkinson’s disease. App' Neuropsychol 1999−6: 129−46.